Slidesets

Share

Program Content

Activities

  • Managing Lower-risk MDS
    Strategies for Managing Very Low-Risk, Low-Risk and Intermediate-Risk MDS
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2022

    Expires: December 08, 2023

    View Activity
  • TX for Higher Risk MDS
    Emerging Therapies in the Treatment of Patients With Higher Risk MDS in Frontline and Post-HMA Failure Settings
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2022

    Expires: December 08, 2023

    View Activity
  • MDS Classification and Risk
    Myelodysplastic Syndromes: Diagnosis, Classification, and Risk Stratification
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2022

    Expires: December 08, 2023

    View Activity
  • EP: MDS Personalized Management
    Express Points An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2022

    Expires: December 20, 2023

    View Activity

Faculty

cover img faculity

Rami Komrokji, MD

Professor
Department of Oncologic Sciences
University of South Florida
Vice Chair
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

cover img faculity

María Díez Campelo, MD, PhD

Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

cover img faculity

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Provided by

ProCE Banner

Supporters

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation